Methods of payment
If you live in Belgium, France, Germany, Ireland, Italy, Portugal, Spain or Sweden and are not registered for VAT we are required to charge VAT at the rate applicable in your country of residence. If you live in any other country in the EU and are not registered for VAT you will be charged VAT at the UK rate. If registered, please quote your VAT number, or the VAT number of any agency paying on your behalf if it is registered.
Transfer of copyright
Please read the notes overleaf and then complete, sign, and return this form to Journals Production, Cambridge University Press, University Printing House, Shaftesbury Road, Cambridge, CB2 8BS, UK as soon as possible.
In 
To be filled in if copyright belongs to you
Transfer of copyright I/we hereby assign to the Collegium Internationale Neuro-Psychopharmacologicum, full copyright in all formats and media in the said contribution, including in any supplementary materials that I/we may author in support of the online version.
I/we warrant that I am/we are the sole owner or co-owners of the contribution and have full power to make this agreement, and that the contribution contains nothing that is in any way an infringement of any existing copyright or licence, or duty of confidentiality, or duty to respect privacy, or any other right of any person or party whatsoever and contains nothing libellous or unlawful; and that all statements purporting to be facts are true and that any recipe, formula, instruction or equivalent published in the Journal will not, if followed accurately, cause any injury or damage to the user.
I/we further warrant that permission has been obtained from the copyright holder for any material not in my/our copyright including any audio and video material, that the appropriate acknowledgement has been made to the original source, and that in the case of audio or video material appropriate releases have been obtained from persons whose voices or likenesses are represented therein. I/we attach copies of all permission and release correspondence.
I/we hereby assert my/our moral rights in accordance with the UK Copyrights Designs and Patents Act (1988) .
Signed (tick one)
□ the sole author(s) □one author authorised to execute this transfer on behalf of all the authors of the above article 
US Government exemption
I/we certify that the paper above was written in the course of employment by the United States Government so that no copyright exists. 
Notes for contributors
1 The Journal's policy is to acquire copyright in all contributions. There are two reasons for this: (a) ownership of copyright by one central organisation tends to ensure maximum international protection against unauthorised use; (b) it also ensures that requests by third parties to reprint or reproduce a contribution, or part of it, are handled efficiently and in accordance with a general policy that is sensitive both to any relevant changes in international copyright legislation and to the general desirability of encouraging the dissemination of knowledge.
2 Two 'moral rights' were conferred on authors by the UK Copyright Act in 1988. In the UK an author's 'right of paternity', the right to be properly credited whenever the work is published (or performed or broadcast), requires that this right is asserted in writing.
3 Notwithstanding the assignment of copyright in their contribution, all contributors retain the following non-transferable rights:
• The right to post either their own version of their contribution as submitted to the journal (prior to revision arising from peer review and prior to editorial input by Cambridge University Press) or their own final version of their contribution as accepted for publication (subsequent to revision arising from peer review but still prior to editorial input by Cambridge University Press) on their personal or departmental web page, or in the Institutional Repository of the institution in which they worked at the time the paper was first submitted, or (for appropriate journals) in PubMedCentral or UK PubMedCentral, provided the posting is accompanied by a prominent statement that the paper has been accepted for publication and will appear in a revised form, subsequent to peer review and/or editorial input by Cambridge University Press, in International Journal of Neuropsychopharmacology published by Cambridge University Press, together with a copyright notice in the name of the copyright holder (Cambridge University Press or the sponsoring Society, as appropriate). On publication the full bibliographical details of the paper (volume: issue number (date), page numbers) must be inserted after the journal title, along with a link to the Cambridge website address for the journal. Inclusion of this version of the paper in Institutional Repositories outside of the institution in which the contributor worked at the time the paper was first submitted will be subject to the additional permission of Cambridge University Press (not to be unreasonably withheld). • The right to post the definitive version of the contribution as published at Cambridge Journals Online (in PDF or HTML form) on their personal or departmental web page, no sooner than upon its appearance at Cambridge Journals Online, subject to file availability and provided the posting includes a prominent statement of the full bibliographical details, a copyright notice in the name of the copyright holder (Cambridge University Press or the sponsoring Society, as appropriate), and a link to the online edition of the journal at Cambridge Journals Online. • The right to post the definitive version of the contribution as published at Cambridge Journals Online (in PDF or HTML form) in the Institutional Repository of the institution in which they worked at the time the paper was first submitted, or (for appropriate journals) in PubMedCentral or UK PubMedCentral, no sooner than one year after first publication of the paper in the journal, subject to file availability and provided the posting includes a prominent statement of the full bibliographical details, a copyright notice in the name of the copyright holder (Cambridge University Press or the sponsoring Society, as appropriate), and a link to the online edition of the journal at Cambridge Journals Online. Inclusion of this definitive version after one year in Institutional Repositories outside of the institution in which the contributor worked at the time the paper was first submitted will be subject to the additional permission of Cambridge University Press (not to be unreasonably withheld). • The right to post an abstract of the contribution (for appropriate journals) on the Social Science Research Network (SSRN), provided the abstract is accompanied by a prominent statement that the full contribution appears in International Journal of Neuropsychopharmacology published by Cambridge University Press, together with full bibliographical details, a copyright notice in the name of the journal's copyright holder (Cambridge University Press or the sponsoring Society, as appropriate), and a link to the online edition of the journal at Cambridge Journals Online. • The right to make hard copies of the contribution or an adapted version for their own purposes, including the right to make multiple copies for course use by their students, provided no sale is involved. • The right to reproduce the paper or an adapted version of it in any volume of which they are editor or author. Permission will automatically be given to the publisher of such a volume, subject to normal acknowledgement.
4 We shall use our best endeavours to ensure that any direct request we receive to reproduce your contribution, or a substantial part of it, in another publication (which may be an electronic publication) is approved by you before permission is given.
5 Cambridge University Press co-operates in various licensing schemes that allow material to be photocopied within agreed restraints (e.g. the CCC in the USA and the CLA in the UK). Any proceeds received from such licences, together with any proceeds from sales of subsidiary rights in the Journal, directly support its continuing publication.
6 It is understood that in some cases copyright will be held by the contributor's employer. If so, the Collegium Internationale Neuro-Psychopharmacologicum requires non-exclusive permission to deal with requests from third parties, on the understanding that any requests it receives from third parties will be handled in accordance with paragraphs 4 and 5 above (note that your approval and not that of your employer will be sought for the proposed use).
Permission to include material not in your copyright
If your contribution includes textual or illustrative material not in your copyright and not covered by fair use / fair dealing, permission must be obtained from the relevant copyright owner (usually the publisher or via the publisher) for the non-exclusive right to reproduce the material worldwide in all forms and media, including electronic publication. The relevant permission correspondence should be attached to this form.
If you are in doubt about whether or not permission is required, please consult the Permissions Manager, Cambridge University Press, The Edinburgh Building, Shaftesbury Road, Cambridge CB2 8RU, UK. Fax: +44 (0)1223 315052. Email: lnicol@cambridge.org.
The information provided on this form will be held in perpetuity for record purposes. The name(s) and address(es) of the author(s) of the contribution may be reproduced in the journal and provided to print and online indexing and abstracting services and bibliographic databases.
Please make a duplicate of this form for your own records 11 Abstract 12 Individual differences in emotional processing are likely to contribute to vulnerability and resilience to 13 emotional disorders such as depression and anxiety. Genetic variation is known to contribute to these 14 differences but they remain incompletely understood. The serotonin transporter (5-HTTLPR) and a 2B -15 adrenergic autoreceptor (ADRA2B) insertion/deletion polymorphisms impact on two separate but inter-16 acting monaminergic signalling mechanisms that have been implicated in both emotional processing and 17 emotional disorders. Recent studies suggest that the 5-HTTLPR s allele is associated with a negative 18 attentional bias and an increased risk of emotional disorders. However, such complex behavioural traits 19 are likely to exhibit polygenicity, including epistasis. This study examined the contribution of the 20 5-HTTLPR and ADRA2B insertion/deletion polymorphisms to attentional biases for aversive information 21 in 94 healthy male volunteers and found evidence of a significant epistatic effect (p<0.001). Specifically, in 22 the presence of the 5-HTTLPR s allele, the attentional bias for aversive information was attenuated by 23 possession of the ADRA2B deletion variant whereas in the absence of the s allele, the bias was enhanced. 24 These data identify a cognitive mechanism linking genotype-dependent serotonergic and noradrenergic 25 signalling that is likely to have implications for the development of cognitive markers for depression/ 26 anxiety as well as therapeutic drug effects and personalized approaches to treatment.
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29 Introduction 30 Enhanced processing of emotionally salient in relation 31 to neutral information is normally considered to be an 32 adaptive process enabling threat detection and in-33 creasing the probability of survival (Vuilleumier, 34 2005) . However, there is considerable evidence that 35 biased processing of emotional information also plays 36 a role in the aetiology and maintenance of emotional 37 disorders such as depression and anxiety (Leppanen, 38 2006 ). Yet in spite of this increasing in-54 sight, the fact that up to 50 % of patients treated with 55 these medications fail to respond adequately remains 56 a significant challenge in the management of these 57 disorders (Souery et al. 1999 ). Inter-individual dif-58 ferences in responses to emotional stimuli may con-59 tribute to differences in vulnerability to emotional 60 disorders as well as response to therapeutic agents 61 (Hamann & Canli, 2004) . It is increasingly accepted 62 that genetic factors explain small but significant 63 amounts of this variability (Todd et al. 2011 ). Thus, 64 polymorphisms in genes involved in serotonergic and 65 noradrenergic signalling represent apposite candi-66 dates for further investigation. 67 One of the genetic variants that have been most ex-68 tensively investigated in relation to human emotional 69 processing and emotional disorders is the gene 70 encoding the serotonin transporter (5-HTT AQ2 or 71 SLC6A4). An insertion/deletion polymorphism in the 72 promoter region of this gene (5-HTTLPR) results in two 73 common allelic variants : short (s) and long (l). The 74 former has been associated with reduced transporter 75 transcription, resulting in approximately 50 % re-76 duction in transporter availability in vitro and pre-77 sumed increased synaptic serotonin availability (Heils 78 et al. 1996) . More recently, an additional A/G single 79 nucleotide polymorphism (SNP) in the l allele (rs25531) 80 has been found to further influence transcriptional 81 activity. The G variant of the l allele is considered to 82 .=24.0¡4.8) were recruited from the uni-170 versity and local community. They had no lifetime 171 history of psychiatric or neurological disorder. Esti-172 mates of verbal IQ were derived from the National 173 Adult Reading Test (NART ; Nelson, 1982) . The study 174 was approved by the local research ethics committee. 175 Following complete description of the study to the 176 participants, written informed consent was obtained. 177 Behavioural task 178 We used an emotional attention blink (AB) task based 179 on dual-target rapid serial visual presentation (RSVP) 180 methodology (Raymond et al. 1992 ). Identification of a 181 first target (T1) in a rapid stream of stimuli leads 182 to transient impairment in identification of a second 183 target (T2) -an effect, known as the attentional blink. 184 It has previously been used by us and others to dem-185 onstrate a bias towards accurate detection of aversive 186 T2 targets compared to neutral (Anderson, 2005 ; 187 Epistasis between 5-HTTLPR and ADRA2B 3 246 modulation of the AB effect was examined in a 247 repeated-measures ANOVA with the same between-248 subjects factors, valence (aversive, neutral) and lag 249 (2, 4, 6) as within-subject factors and percent correct T2 250 report (contingent on the correct identification of T1)# 251 as the dependent measure. Significant interactions 252 were explored using post-hoc t tests. A Greenhouse-253 Geisser correction was applied where sphericity as-254 sumptions were violated. 255 Results 256 Genotypes 257 Of the 107 participants, ADRA2B genotypes were un-258 available for two participants, 11 were homozygous 259 carriers of the ADRA2B deletion, 48 were hetero-260 zygotes and 46 were non-carriers, consistent with 261 HWE (x 2 =0.09, p=0.77). Due to the small number of 262 homozygous carriers, they were combined with the 263 heterozygotes, giving two genotype groups of deletion 264 carriers (Del) and non-carriers (Ins) as previously done 265 # This is to guarantee that proper attention has been devoted to T1 to ensure an AB effect. 319 paradigm. To our knowledge, this is the first study to 320 examine the contribution of the ADRA2B insertion/ 321 deletion polymorphism to individual differences in 322 emotional attentional biases and only the second study 323 to explore the genetic basis of the emotional AB effect 324 [Munafò and colleagues previously found an associ-325 ation between 5-HTTLPR genotype, smoking status 326 and detection of smoking-related stimuli in an AB task 327 (Munafò et al. 2005) ]. The significant novel finding 328 from this study is that the affective modulation of T2 329 detection is influenced by a non-additive (epistatic) 330 interaction between the ADRA2B and 5-HTTLPR in-331 sertion/deletion polymorphisms. 332 Specifically, we found that a significant attentional 333 bias for aversive compared to neutral information was 334 present in individuals possessing at least one copy of 335 the short (s) allele of 5-HTTLPR, but only if they did 336 not carry the ADRA2B deletion. Conversely, the at-337 tentional bias for emotional information was only 338 present in 5-HTTLPR long (l) allele homozygotes if 339 they were ADRA2B deletion carriers. This suggests 340 that in the presence of the 5-HTTLPR s allele which is a 341 putative risk allele for depressive and anxiety dis-342 orders, the negative attentional bias is attenuated by 343 the ADRA2B deletion variant whereas in the absence 344 of the s allele, the bias is enhanced. Both of these effects 345 may be related to adaptive processes. For instance, 346 dependent on 5-HTTLPR genotype, the effect of the 347 ADRA2B deletion variant may be to either exert a 348 protective effect against affective spectrum disorders 349 or facilitate enhanced detection of threat, in both cases 350 contributing to increased probability of survival. 351 Behavioural genetics implications 352 We did not find a main effect of the serotonin trans-353 porter polymorphism The effect of the ADRA2B insertion/deletion 390 polymorphism on attentional biases for emotional 391 information has not been previously investigated. 392 However, it has been suggested that it might contrib-393 ute to the emotional memory bias observed in 394 ADRA2B deletion carriers (Todd & Anderson, 2009 ). 395 We did not find any main effect of ADRA2B on ), although none of these studies 517 included the ADRA2B polymorphism. The GENDEP 518 project did examine a polymorphism in the related 519 ADRA2A gene encoding a 2A -adrenoceptor subtype 520 but failed to find any significant effect despite a 521 previously reported association with the response 522 to the serotonin-noradrenaline reuptake inhibitor 523 milnacipran (Wakeno et al. 2008 ). Of note, neither of 524 the two antidepressants evaluated in GENDEP was a 525 molecular target of the a 2 -adrenoceptor group. 526 Thus, the role of polymorphic variation in a 2 -527 adrenergic receptors (and their interaction with sero-528 tonergic targets) in the therapeutic response of 529 patients with affective spectrum disorders warrants 530 further investigation. 531 Study limitations 532 The purpose of this study was to investigate epistatic 533 effects of serotonergic and noradrenergic genes on 534 emotional attentional biases. However, the fact that we 535 measured only two polymorphisms out of a number 536 that might contribute to the behavioural effect of in-537 terest represents a limitation to this study. Most sig-538 nificantly, we were unable to genotype the additional 539 rs25531 SNP in the long allele of the 5-HTT gene. 540 However, given that the prevalence of the L G allele 541 is low (y10 %), this is unlikely to have significantly 542 biased our findings. A further limitation is that al-543 though the overall sample size was reasonable, there 544 were relatively few individuals in some genotype 545 combinations. This is a particular difficulty inherent in 546 measuring epistatic gene effects (Moore, 2008) . Future 547 studies will need to use large sample sizes and evolv-548 ing methodologies to effectively evaluate the likely 549 effects on emotional processing of multiple gene in-550 teractions (Cordell, 2009 ). The final limitation is that 551 we only used aversive stimuli and male volunteers. 552 While the latter eliminated possible biases associated 553 with gender differences in emotional processing, it 554 limits the generalizability of our findings. It is there-555 fore unclear whether the observed biases are valence 556 and/or gender specific. Additionally the aversive 557 stimuli used included range of negative emotions 558 (disgust, fear, sadness) rather than specifically dys-559 phoric or threat-related emotions. It is therefore un-560 clear how these processing biases might map onto 561 those considered to relate to depression and anxiety 562 disorders. Further studies with larger sample sizes 563 including men and women will be required to repli-564 cate and extend our findings. 565 
Conclusions

566
In spite of these limitations, this study begins to con- 
